サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426170

関節炎モノクローナル抗体の世界市場レポート 2024

Arthritis Monoclonal Antibodies Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
関節炎モノクローナル抗体の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

関節炎モノクローナル抗体の市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には7.7%の年間複合成長率（CAGR）で837億6,000万米ドルに成長すると予想されます。予測期間の予想される成長は、併用療法の採用、これらの治療の適応拡大、患者の嗜好の高まり、ヘルスケア全体の増加などのいくつかの要因により予想されます。

関節炎の世界の蔓延は、主に変形性関節症、痛風、線維筋痛症、関節リウマチによって3億5,000万人以上に影響を与えており、関節炎モノクローナル抗体市場を著しく押し上げています。 2021年、関節リウマチは世界中で0.3%～1%に及び、変形性関節症は男性の約9.6%、女性の18%に影響を及ぼしています。この関節炎症例の急増は、個別化医療に対する需要の高まりと相まって、市場の成長を促進しています。

個別化医薬品の承認の急増は、関節炎モノクローナル抗体市場を推進する重要な原動力となっています。遺伝子やバイオマーカーのプロファイルなど、個々の患者の特性に合わせて調整された個別化医療は、治療反応に革命をもたらしています。この個別化医療のトレンドを代表するモノクローナル抗体は、患者の転帰を大幅に向上させる可能性を秘めています。注目すべきことに、The Personalized Medicine Coalitionによれば、2021年にFDAのCDERは50の新しい分子エンティティのうち35%を個別化医療として承認し、関節炎モノクローナル抗体市場をさらに促進しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の関節炎モノクローナル抗体市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • レミケード
  • ヒュミラ
  • エンブレル
  • リツキサン
  • オレンシア
  • アクテムラ
  • シンポニ
  • シムジア
  • レムシマ
  • 世界の関節炎モノクローナル抗体市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 関節リウマチ
  • 変形性関節症
  • 乾癬性関節炎
  • 強直性脊椎炎
  • 線維筋痛症
  • その他の用途
  • 世界の関節炎モノクローナル抗体市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 研究機関
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の関節炎モノクローナル抗体市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の関節炎モノクローナル抗体市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 関節炎モノクローナル抗体市場の競合情勢
  • 関節炎モノクローナル抗体市場企業プロファイル
    • Johnson &Johnson
    • Hoffmann-La Roche Ltd.
    • Novartis AG
    • Pfizer Inc.
    • AbbVie Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13192

Arthritis monoclonal antibodies represent an advanced class of biological medications specifically utilized for treating rheumatoid arthritis and immune-mediated inflammatory conditions. These medications work by inhibiting interleukin-6, a key inflammatory protein, thereby alleviating joint pain, swelling, and other inflammation-related symptoms. Additionally, they play a role in reducing the body's defense mechanism to prevent rejection of newly transplanted organs.

The primary types of drugs in this category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade, for instance, is prescribed for individuals with moderately to severely active Crohn's disease who haven't responded well to other treatments. These medications find application across various conditions such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, among others. Their utilization spans multiple sectors including hospitals, research institutes, and other healthcare domains.

The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2023 to $62.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to several factors. These include the escalating prevalence of arthritis, heightened awareness regarding the efficacy of arthritis monoclonal antibodies, a widening array of approved medications in this category, governmental support for research and development initiatives, and increased investments from pharmaceutical companies within this domain.

The arthritis monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. Anticipated growth in the forecast period is expected due to several factors, including the adoption of combination therapies, the expansion of indications for these treatments, growing patient preferences, and an overall increase in healthcare expenditure.

The escalating global prevalence of arthritis, affecting over 350 million individuals, predominantly through osteoarthritis, gout, fibromyalgia, and rheumatoid arthritis, has notably boosted the arthritis monoclonal antibody market. In 2021, Rheumatoid arthritis spans 0.3% to 1% worldwide, while osteoarthritis affects approximately 9.6% of men and 18% of women. This surge in arthritis cases, coupled with a growing demand for personalized medicine, is fueling the market's growth.

The surge in approvals for personalized medicines is a significant driver propelling the arthritis monoclonal antibody market. Personalized medicines, tailored to individual patient characteristics, including genetic and biomarker profiles, are revolutionizing treatment responses. Monoclonal antibodies, representing this personalized medicine trend, have the potential to enhance patient outcomes significantly. Notably, in 2021, the FDA's CDER greenlit 35% of its 50 new molecular entities as personalized medicines, according to The Personalized Medicine Coalition, further catalyzing the arthritis monoclonal antibody market.

The evolution of therapeutic monoclonal antibody products stands as a pivotal force in advancing the arthritis monoclonal antibody market. These highly efficient, target-specific antibodies excel in treating arthritis, surpassing small molecules and peptides. The market's expansion is evident through the introduction of a multitude of monoclonal antibody drugs dedicated to arthritis treatment, signifying enhanced therapeutic options.

Leading players in the arthritis monoclonal antibody market are introducing cost-effective biosimilar versions like Hulio to ensure more accessible treatment options. Hulio, a biosimilar variant of AbbVie's Humira, a prominent rheumatoid arthritis drug, was launched by Biocon Biologics in July 2023. Priced at a 5% discount to Humira, which currently stands at $6,922 per carton, Hulio caters to conditions like rheumatoid arthritis and psoriatic arthritis, aiming to make treatment more affordable.In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.

Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca PLC, Mylan N.V., Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arthritis Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on arthritis monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for arthritis monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthritis monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima
  • 2) By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Other Applications
  • 3) By End-Use: Hospitals; Research Institutes; Other End-Users
  • Companies Mentioned: Johnson & Johnson; Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Arthritis Monoclonal Antibodies Market Characteristics

3. Arthritis Monoclonal Antibodies Market Trends And Strategies

4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Arthritis Monoclonal Antibodies Market Size and Growth

  • 5.1. Global Arthritis Monoclonal Antibodies Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Arthritis Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Arthritis Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Arthritis Monoclonal Antibodies Market Segmentation

  • 6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Remicade
  • Humira
  • Enbrel
  • Rituxan
  • Orencia
  • Actemra
  • Simponi
  • Cimzia
  • Remsima
  • 6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Fibromyalgia
  • Other Applications
  • 6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Institutes
  • Other End-Users

7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis

  • 7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Arthritis Monoclonal Antibodies Market

  • 8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Arthritis Monoclonal Antibodies Market

  • 9.1. China Arthritis Monoclonal Antibodies Market Overview
  • 9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Arthritis Monoclonal Antibodies Market

  • 10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Arthritis Monoclonal Antibodies Market

  • 11.1. Japan Arthritis Monoclonal Antibodies Market Overview
  • 11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Arthritis Monoclonal Antibodies Market

  • 12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Arthritis Monoclonal Antibodies Market

  • 13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Arthritis Monoclonal Antibodies Market

  • 14.1. South Korea Arthritis Monoclonal Antibodies Market Overview
  • 14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Arthritis Monoclonal Antibodies Market

  • 15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview
  • 15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Arthritis Monoclonal Antibodies Market

  • 16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Arthritis Monoclonal Antibodies Market

  • 17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Arthritis Monoclonal Antibodies Market

  • 18.1. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Arthritis Monoclonal Antibodies Market

  • 19.1. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Arthritis Monoclonal Antibodies Market

  • 20.1. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Arthritis Monoclonal Antibodies Market

  • 21.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview
  • 21.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Arthritis Monoclonal Antibodies Market

  • 22.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Arthritis Monoclonal Antibodies Market

  • 23.1. North America Arthritis Monoclonal Antibodies Market Overview
  • 23.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Arthritis Monoclonal Antibodies Market

  • 24.1. USA Arthritis Monoclonal Antibodies Market Overview
  • 24.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Arthritis Monoclonal Antibodies Market

  • 25.1. Canada Arthritis Monoclonal Antibodies Market Overview
  • 25.2. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Arthritis Monoclonal Antibodies Market

  • 26.1. South America Arthritis Monoclonal Antibodies Market Overview
  • 26.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Arthritis Monoclonal Antibodies Market

  • 27.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Arthritis Monoclonal Antibodies Market

  • 28.1. Middle East Arthritis Monoclonal Antibodies Market Overview
  • 28.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Arthritis Monoclonal Antibodies Market

  • 29.1. Africa Arthritis Monoclonal Antibodies Market Overview
  • 29.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles

  • 30.1. Arthritis Monoclonal Antibodies Market Competitive Landscape
  • 30.2. Arthritis Monoclonal Antibodies Market Company Profiles
    • 30.2.1. Johnson & Johnson
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Pfizer Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Arthritis Monoclonal Antibodies Market Competitive Benchmarking

32. Global Arthritis Monoclonal Antibodies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market

34. Arthritis Monoclonal Antibodies Market Future Outlook and Potential Analysis

  • 34.1 Arthritis Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Arthritis Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Arthritis Monoclonal Antibodies Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer